Projects per year
Personal profile
Biography
A/Prof Kate Webber is a medical oncologist at Monash Health, where she serves as stream lead for gynaecological cancer within the oncology unit. She has subspecialty expertise in breast and gynaecological cancers, cancer survivorship and patient reported outcomes research. Dr Webber’s PhD and subsequent research has encompassed studies exploring the prevalence, predictors and trajectories of physical and psychological symptoms after cancer treatment, lifestyle and behavioural interventions, and novel models of delivery of survivorship care. Dr Webber is an active member of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG) and has served as an investigator on over 40 gynaecological cancer clinical trials. A/Prof Webber is also passionate about supporting translation of clinical trial evidence into practice, and as such has served as the co-chair of the Cancer Institute NSW eviQ Medical Oncology Reference Committee from 2019-2023. A/Prof Webber is the deputy chair of the Clinical Oncology Society of Australia Survivorship Group and serves on its Patient Reported Outcomes Working Group. She leads a research team at Monash Health which is exploring implementation of real time patient reported outcome measures into routine cancer care.
A/Prof Webber graduated from the University of New South Wales in 2002 with first class honours and completed her specialty training in medical oncology at St George and Prince of Wales Hospitals in Sydney. She was then appointed the inaugural Survivorship Research Fellow at the National Centre for Cancer Survivorship at the University of New South Wales where she completed her PhD. Prior to her appointment at Monash Health, A/Prof Webber held staff specialist appointments in medical oncology at Prince of Wales Hospital and the Royal Hospital for Women in Sydney, as well as an honorary appointment at Sydney Children’s Hospital, and a conjoint lecturer position at UNSW. At Prince of Wales Hospital she also served as Clinical Superintendent for Medicine and co-Director of Advanced Physician Training, as well as convenor of the UNSW Human Research Ethics Advisory Panel (Biomedical).
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, University of New South Wales (UNSW)
Award Date: 21 Sept 2016
FRACP, Royal Australasian College of Physicians (RACP)
Award Date: 8 Dec 2010
B.Sc(Med) MBBS (honours class 1), University of New South Wales (UNSW)
Award Date: 13 Dec 2002
External positions
eviQ Medical Oncology Co-chair, Cancer Institute NSW (New South Wales)
30 Aug 2019 → …
Medical oncologist, Monash Health
3 Dec 2018 → …
Collaborations and top research areas from the last five years
-
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
Webber, K. (Primary Chief Investigator (PCI))
21/10/25 → 20/10/30
Project: Research
-
A randomized Phase 2, open-label study of mirvetuximab soravtansine in patients with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression testing 2 schedules of administration for dose optimization, with a separate cohort to determine starting dose in patients with moderate hepatic impairment
Webber, K. (Primary Chief Investigator (PCI))
15/07/25 → 14/07/30
Project: Research
-
A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers
Webber, K. (Primary Chief Investigator (PCI))
17/06/25 → 16/06/30
Project: Research
-
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Webber, K. (Primary Chief Investigator (PCI))
23/12/24 → 22/12/29
Project: Research
-
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
Webber, K. (Primary Chief Investigator (PCI))
21/10/24 → 20/10/29
Project: Research
-
Aligning kidney function assessment in patients with cancer to global practices in internal medicine
Sandhu, G., Adattini, J., Gordon, E. A., O'Neill, N., Bagnis, C., Chambers, P., Martin, J. H., Flynn, A., Ibrahim, K., Jardine, M. J., Johnson, D. W., Jones, G. R. D., Karapetis, C. S., Kelly, A., Kichenadasse, G., Kliman, D. S., Liauw, W., Lucas, C., Mallett, A. J. & Malyszko, J. & 15 others, , Apr 2025, In: eClinicalMedicine. 82, 11 p., 103102.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access1 Citation (Scopus) -
Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study
Sassé, B., Shaya, S., Nimmo, J., Cao, K., Day, D., Evans, K., Healy, C., Ho, G. Y., Kruss, G., McCartney, A., Mojzisova, L., Srivastava, R., Tan, J., Tan, M. Y., Webber, K., White, M., David, S. & Harris, M., Feb 2025, In: The Breast. 79, 6 p., 103861.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice
Sandhu, G., Adattini, J., Armstrong Gordon, E., O'Neill, N., Bagnis, C., Boddy, A. V., Chambers, P., Flynn, A., Hamilton, B., Ibrahim, K., Johnson, D. W., Karapetis, C., Kelly, A., Kerr, K. A., Kichenadasse, G., Kliman, D. S., Kurkard, C., Liauw, W., Lucas, C. & Mallett, A. J. & 20 others, , Apr 2025, In: eClinicalMedicine. 82, 11 p., 103161.Research output: Contribution to journal › Review Article › Research › peer-review
Open Access1 Citation (Scopus) -
Patient-reported outcomes (PROs) as personalised cancer care: report from a 2023 Australian consensus meeting (PROActive)
Mazariego, C. G., Avery, S., Delaney, G. P., Fardell, J. E., Hayes, S., Haywood, D., Lai-Kwon, J., Nolte, S., Pearson, J., Roberts, N. A., Signorelli, C., Taylor, N., Webber, K. & Koczwara, B., Jul 2025, In: eClinicalMedicine. 85, 5 p., 103295.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
Providing Outpatient Oncology Mental Health Support: Understanding Staff Perspectives
Matthews, E., Webber, K., Wiley, J. F. & Parker, C., Jun 2025, In: Psycho-Oncology. 34, 6, 8 p., e70206.Research output: Contribution to journal › Article › Research › peer-review
Open Access
Prizes
-
-
-
The United Medical Protection Prize in Health Law and Ethics
Webber, K. (Recipient), 1999
Prize: Prize (including medals and awards)